KRN7000 applied to adjuvant research

A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy

A semisynthetic carbohydrate-lipid vaccine that protects against S. pneumoniae in mice

Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma

Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants

NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B cell lymphoma

Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses

Activated iNKT Cells Promote Memory CD8(+) T Cell Differentiation during Viral Infection

Intranasal but not intravenous delivery of the adjuvant alpha-galactosylceramide permits repeated stimulation of natural killer T cells in the lung

α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice

Unraveling Molecular Signatures of Immunostimulatory Adjuvants in the Female Genital Tract through Systems Biology

Th17 cells contribute to nontypeable Haemophilus influenzae-specific protective immunity induced by nasal vaccination with P6 outer membrane protein and α-galactosylceramide

Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine

Retinoic Acid and {alpha}-Galactosylceramide Differentially Regulate B Cell Activation In Vitro and Augment Antibody Production In Vivo

An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity

Exploiting the Role of Endogenous Lymphoid-Resident Dendritic Cells in the Priming of NKT Cells and CD8+ T Cells to Dendritic Cell-Based Vaccines

Adjuvant activity mediated by iNKT cells

DNA vaccine with alpha-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells

Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx

Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide

Novel adjuvants for B cell immune responses

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy

Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein

CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies

Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice

Adjuvant effect of alpha-galactosylceramide (alpha-GalCer) in mice upon intravenous administration of antigen plus alpha-GalCer.

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.

Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin

Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity

The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor

Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity

In vitro induction of natural killer T cells from embryonic stem cells prepared using somatic cell nuclear transfer

B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity

Adjuvant Effects of an NKT Ligand, alpha-Galactosylceramide, on DNA Vaccination

Alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors

Role of NKT cells to assist priming of antigen-specific T-cell responses

Invariant NKT cells sustain specific B cell responses and memory

Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide

Back to top

 

New 7DW8-5 glycolipid

7DW8-5

Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch

 

Meet Funakoshi Company
at the following meetings:

AACR
Washington DC
April 1-5, 2017

The 11th Annual Meeting of Japanese Society for Epigentics
Tokyo, Japan
May 22-23, 2017

The 36th Annual Meeting of Japanese Association of Forensic Toxicology

The 21st Annual Meeting of Japanese Assocation of Cancer Immunology
Chiba, Japan
June 28-30, 2017

The Japanese Society for Genome Editing
Osaka, Japan
June 28-30, 2017

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

NIH Festival
Bethesda, Maryland
September 2017

ASCB
Philadelphia, PA
December 2-6, 2017